Supply order for Covishield was placed after drug regulator's nod: Govt

The Rajya Sabha was informed about this on Tuesday

Covishield
Representational image of Covishield
Press Trust of India New Delhi
1 min read Last Updated : Feb 02 2021 | 2:32 PM IST

For the procurement of COVID-19 vaccines, a supply order dated January 11 was placed with the Serum Institute of India after Covishield was approved for restricted use in emergency situation by India's drug regulator, the Rajya Sabha was informed on Tuesday.

Union Minister of State for Health Ashwini Choubey was responding to a question on whether the government has finalised a pricing and supply agreement with the Serum Institute of India Limited for COVID-19 vaccines.

Covishield is being manufactured by the Pune-based firm with technology transfer from AstraZeneca/Oxford University.

On whether it is a fact that multiple doses of the vaccine produced for India could not be rolled out despite approval due to the lack of a formal agreement for supply, Choubey, in a written reply, said, " No. As per protocol, the supply order for COVID-19 vaccines, specifying the number of vaccine doses, was placed with the manufacturer and vaccines were delivered within 3 days to the states and UTs and other consignee points.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Coronavirus VaccineBharat BiotechRajya Sabha

First Published: Feb 02 2021 | 2:30 PM IST

Next Story